Literature DB >> 20084020

Expression of PROX1 Is a common feature of high-grade malignant astrocytic gliomas.

Tamador Elsir1, Anna Eriksson, Abiel Orrego, Mikael S Lindström, Monica Nistér.   

Abstract

PROX1 is a prospero-related transcription factor that plays a critical role in the development of various organs including the mammalian lymphatic and central nervous systems; it controls cell proliferation and differentiation through different transcription pathwaysand has both oncogenic and tumor-suppressive functions. We investigated PROX1 expression patterns in 56 human astrocytic gliomas of different grades using immunohistochemistry. An average of 79% of cells in World Health Organization Grade IV (glioblastoma, n = 15) and 57% of cells in World Health Organization Grade III (anaplastic astrocytoma, n = 13) were strongly PROX1 positive; low-grade diffuse astrocytomas (Grade II, n = 13) had 21% of cells that were strongly positive; Grade I tumors (n = 15) had 1.5%; and non-neoplastic brain tissue (n = 15) had 3.7% of cells that were PROX1 positive. Double immunolabeling showed that PROX1+ cells in glioblastomas frequently coexpressed early neuronal proteins MAP2 and betaIII-tubulin but not the mature neuronal marker protein NeuN. Analyses of coexpression with proliferation markers suggest that PROX1+ cells have a marginally lower rate of proliferation than other tumor cells but are still mitotically active. We conclude that PROX1 may constitute a useful tool for the diagnosis and grading ofastrocytic gliomas and for distinguishing Grade III and Grade IV tumors from Grade I and Grade II tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20084020     DOI: 10.1097/NEN.0b013e3181ca4767

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  26 in total

1.  Prospero homeobox 1 mediates the progression of gastric cancer by inducing tumor cell proliferation and lymphangiogenesis.

Authors:  Kang-Jin Park; Sung-Bum Cho; Young-Lan Park; Nuri Kim; Sun-Young Park; Dae-Seong Myung; Wan-Sik Lee; Sun-Seog Kweon; Young-Eun Joo
Journal:  Gastric Cancer       Date:  2016-01-12       Impact factor: 7.370

2.  PROX1 lymphatic density correlates with adverse clinicopathological factors, lymph node metastases and survival in neuroblastomas.

Authors:  Pramila Ramani; Aimie Norton; Michelle S Somerville; Margaret T May
Journal:  J Neurooncol       Date:  2012-03-01       Impact factor: 4.130

Review 3.  Recent advances and future of immunotherapy for glioblastoma.

Authors:  Neha Kamran; Alexandra Calinescu; Marianela Candolfi; Mayuri Chandran; Yohei Mineharu; Antonela S Asad; Carl Koschmann; Felipe J Nunez; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2016-07-27       Impact factor: 4.388

4.  Prox1 inhibits neurite outgrowth during central nervous system development.

Authors:  Valeria Kaltezioti; Iosifina P Foskolou; Matthieu D Lavigne; Elpinickie Ninou; Matina Tsampoula; Maria Fousteri; Marigoula Margarity; Panagiotis K Politis
Journal:  Cell Mol Life Sci       Date:  2020-11-28       Impact factor: 9.261

5.  The homeobox transcription factor Prox1 inhibits proliferation of hepatocellular carcinoma cells by inducing p53-dependent senescence-like phenotype.

Authors:  Tsung-Ming Chang; Wen-Chun Hung
Journal:  Cancer Biol Ther       Date:  2013-01-04       Impact factor: 4.742

Review 6.  Molecular alterations in glioblastoma: potential targets for immunotherapy.

Authors:  Azizul Haque; Naren L Banik; Swapan K Ray
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

7.  ASYMMETRIC CELL DIVISION: IMPLICATIONS FOR GLIOMA DEVELOPMENT AND TREATMENT.

Authors:  Kate Marie Lewis; Claudia Petritsch
Journal:  Transl Neurosci       Date:  2013-12       Impact factor: 1.757

8.  Impact of prospero homeobox-1 on tumor cell behavior and prognosis in colorectal cancer.

Authors:  Young-Lan Park; Eun Myung; Sun-Young Park; Nuri Kim; Chan-Young Oak; Dae-Seong Myung; Sung-Bum Cho; Wan-Sik Lee; Sun-Seog Kweon; Hyun-Soo Kim; Young-Eun Joo
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

9.  PROX1 is a predictor of survival for gliomas WHO grade II.

Authors:  T Elsir; M Qu; S G Berntsson; A Orrego; T Olofsson; M S Lindström; M Nistér; A von Deimling; C Hartmann; D Ribom; A Smits
Journal:  Br J Cancer       Date:  2011-05-10       Impact factor: 7.640

Review 10.  Cellular-based immunotherapies for patients with glioblastoma multiforme.

Authors:  Xun Xu; Florian Stockhammer; Michael Schmitt
Journal:  Clin Dev Immunol       Date:  2012-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.